BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 30,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 30,000 shares of the business’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00. Following the transaction, the chief executive officer directly owned 380,209 shares of the company’s stock, valued at $37,792,774.60. This trade represents a 7.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.

BioNTech Stock Up 0.8%

Shares of BNTX opened at $99.26 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The stock has a market capitalization of $25.10 billion, a price-to-earnings ratio of -12.68 and a beta of 1.29. The stock has a fifty day moving average of $98.03 and a 200-day moving average of $94.76.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same quarter in the prior year, the firm earned ($1.60) EPS. The company’s revenue was down 59.5% on a year-over-year basis. As a group, sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently modified their holdings of the company. Monaco Asset Management SAM bought a new position in BioNTech during the fourth quarter worth $1,594,000. Hsbc Holdings PLC bought a new stake in BioNTech during the fourth quarter valued at $4,969,000. Bank of America Corp DE boosted its position in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the period. Finally, Amundi grew its holdings in BioNTech by 24.5% during the 1st quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after acquiring an additional 25,506 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on BNTX shares. Canaccord Genuity Group lowered their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $128.00 to $105.00 in a research report on Tuesday, September 8th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Citigroup decreased their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Finally, Morgan Stanley dropped their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.